Evaluation of PTX/Mo(2)CTx-MXene@Fuc surface-engineered nanosheets in targeted combination therapy for triple-negative breast cancer

评估 PTX/Mo(2)CTx-MXene@Fuc 表面工程纳米片在三阴性乳腺癌靶向联合治疗中的应用

阅读:1

Abstract

AIMS: The study aimed to evaluate the multifunctional therapeutic potential of PTX/Mo(2)CTx-MXene@Fuc combinations, emphasizing their performance in drug loading, release kinetics, oxidative stress induction, apoptosis, cell migration, and angiogenesis inhibition in cancer therapy. METHODS/MATERIALS: Mo(2)CTx-MXene@Fuc were synthesized and loaded with the chemotherapeutic drug Paclitaxel (PTX) to achieve pH- and NIR-responsive release. In vitro cytotoxicity, ROS generation, apoptosis, migration, and tube-formation assays were performed on cancer (4T1, MDA-MB-231) and normal (L929) cell lines under NIR (808 nm) irradiation. RESULTS: The nanosheets exhibited high PTX loading efficiency (85-90%) and pH-sensitive drug release, with accelerated release in acidic tumor-mimicking environments. NIR irradiation significantly enhanced ROS production in cancer cells while maintaining low oxidative activity in normal cells. Apoptosis assays confirmed pronounced cell death under NIR+ conditions, while migration and tube-formation analyses revealed that MXene nanosheets moderately inhibited cell motility and suppressed endothelial angiogenesis. These results demonstrated synergistic enhancement of photothermal, photodynamic, and chemotherapeutic effects. CONCLUSION: The findings indicate that PTX/Mo(2)CTx-MXene@Fuc nanosheets function as a multifunctional nanoplatform combining chemo-, photothermal-, and photodynamic-therapy mechanisms. Their selective cytotoxicity, ROS-mediated apoptosis, and anti-angiogenic activity highlight their strong potential for future targeted cancer therapy applications.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。